中国经济网北京10月21日讯 今日，平安基金公告，平安中证汽车零部件主题ETF、平安中证光伏 产业ETF、平安中证新能源汽车产业ETF、平安中证新材料主题ETF、平安中证新能源汽车ETF发起联 接、平安中证汽车零部件主题ETF联接增聘马浩然。 马浩然曾任海通证券股份有限公司零售分析师、东吴证券股份有限公司策略分析师、国泰海通证券 股份有限公司资深策略分析师。2025年6月加入平安基金管理有限公司，现任基金经理。 平安中证汽车零部件主题ETF成立于2024年4月29日，截至2025年10月20日，其今年来收益率为 29.60%，成立来收益率为36.57%，累计净值为1.3657元。 平安中证光伏产业ETF成立于2021年2月9日，截至2025年10月20日，其今年来收益率为19.99%，成 立来收益率为-24.92%，累计净值为0.7508元。 平安中证新能源汽车产业ETF成立于2019年12月31日，截至2025年10月20日，其今年来收益率为 47.49%，成立来收益率为133.20%，累计净值为2.3327元。 平安中证新材料主题ETF成立于2021年7月9日，截至2025年10月20日，其今年来收益率为 ...

Group 1 - Trina Solar (688599.SH) reported its semi-annual results for 2025, with 21 institutional investors holding a total of 1.006 billion shares, representing 46.14% of the company's total share capital as of August 22, 2025 [1] - The top ten institutional investors collectively hold 45.83% of the shares, with a slight decrease of 0.46 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, four funds increased their holdings, accounting for a 0.90% increase, while two funds saw a slight decrease in holdings [2] - Seven new public funds were disclosed during this period, including several ETFs focused on the Sci-Tech Innovation Board [2] - One foreign fund, Hong Kong Central Clearing Limited, reduced its holdings by 0.60% compared to the previous quarter [2]

Core Viewpoint - The ETF performance in the first half of 2025 shows a stark contrast, with the Hong Kong innovative drug ETFs surging over 58%, while the photovoltaic industry ETFs faced a decline of over 11% [2][3]. Group 1: Performance of Innovative Drug ETFs - The top-performing ETFs are dominated by the pharmaceutical sector, particularly focusing on Hong Kong innovative drugs and biotechnology, indicating strong investor interest in the innovative drug field [3]. - The leading ETF, Huatai-PB Hong Kong Innovative Drug ETF, achieved a remarkable increase of 58.77%, with a scale of 7.802 billion [4]. - Other notable ETFs include Yinhua and Wanji's Hong Kong Innovative Drug ETFs, both exceeding 57% growth, showcasing significant capital involvement in the sector [4][5]. Group 2: Performance of Photovoltaic and Traditional Energy ETFs - In stark contrast, the coal and photovoltaic industry ETFs experienced significant declines, with the top loser, Guotai Zhongzheng Coal ETF, dropping by 12.28% [6][7]. - The photovoltaic ETFs collectively faced severe downturns, with all listed ETFs in this category recording declines exceeding 11%, reflecting the industry's adjustment pressures [7][8]. Group 3: Underlying Market Dynamics - The extreme market divergence reflects a sensitive response to changes in industry trends, driven by supportive policies for innovative drugs and the challenges faced by traditional energy and photovoltaic sectors [9]. - Recent policies from various government departments have provided robust support for the innovative drug industry, enhancing its development prospects [9][10]. - Conversely, the photovoltaic sector is grappling with overcapacity and financial losses, with expectations for a prolonged adjustment period before recovery [10]. Group 4: Future Outlook - The innovative drug market in China is projected to have significant growth potential, driven by low per capita medical spending and an aging population [11]. - The Hong Kong innovative drug sector is expected to continue its rapid development, supported by policy initiatives and advancements in research and commercialization [11][12]. - Long-term perspectives suggest that innovative drugs represent a "long slope, thick snow" sector, emphasizing the importance of distinguishing between thematic speculation and value growth [12].

Core Insights - The A-share market in the first half of 2025 exhibited a distinct structural trend, with pharmaceutical and biotechnology-themed funds dominating performance rankings [1] - Over 120 funds were liquidated during this period, indicating significant market shifts [1] Performance Summary Top Performing Funds - The top ten stock funds saw significant returns, with the leading fund, Huaan Pharmaceutical Bio A, achieving a return of 66.44% [2] - Other notable performers included Jiashi Huron Selected A (60.26%) and Ping An Pharmaceutical Selected A (58.80%) [2] - The average return of the top ten funds was driven primarily by smaller, actively managed funds, highlighting their flexibility in capturing rapid market movements [5] Underperforming Funds - The worst-performing funds were led by Jianxin China Manufacturing 2025 A, which recorded a decline of 14.68% [4] - Other funds in the bottom tier included Huaxia Advantage Selected and Great Wall Quantitative Selected A, both with declines exceeding 12% [4] - The coal and photovoltaic sectors faced significant downward pressure, with several funds in these categories showing substantial losses [4] Sector Analysis Pharmaceutical and Biotechnology - The pharmaceutical and biotechnology sectors have seen a resurgence after a prolonged adjustment period, driven by improved valuations and supportive policies [5] - The global and domestic biotech investment climate is recovering, contributing to the strong performance of related funds [5] Coal and Photovoltaic Industries - The coal industry is experiencing a shift in supply-demand dynamics, leading to downward pressure on valuations due to economic restructuring and accelerated energy transitions [5] - The photovoltaic sector is facing intensified competition and concerns over overcapacity, impacting short-term profitability and stock performance [5] Market Outlook - The A-share market is expected to show a trend of gradual upward movement in the second half of 2025, supported by increased participation from public funds and favorable policies [6] - However, significant differentiation among sectors may lead to rebalancing pressures, particularly in pharmaceuticals and biotechnology [6] - Investors are advised to analyze macroeconomic trends and industry policies to identify opportunities amidst market volatility [6]

Market Overview - The Shanghai Composite Index rose by 0.86% to close at 3403.95 points, with a daily high of 3417.31 points [1] - The Shenzhen Component Index increased by 0.64% to close at 10354.22 points, reaching a high of 10418.44 points [1] - The ChiNext Index saw a rise of 1.01%, closing at 2083.14 points, with a peak of 2103.37 points [1] ETF Market Performance - The median return for stock ETFs was 0.66%, with the highest return from the Fortune Growth Enterprise 50 ETF at 2.31% [2] - The highest performing industry ETF was the CCB CSI All Share Securities Company ETF, yielding 3.71% [2] - The top thematic ETF was the Dachen CSI Engineering Machinery Theme ETF, which achieved a return of 9.98% [2] ETF Performance Rankings - The top three ETFs by return were: - Dachen CSI Engineering Machinery Theme ETF (9.98%) - Huafu CSI Securities Company Pioneer Strategy ETF (4.61%) - E Fund CSI 300 Non-Bank Financial ETF (4.22%) [4][5] - The ETFs with the largest declines included: - Guotai CSI Photovoltaic Industry ETF (-1.35%) - Huaan CSI Photovoltaic Industry ETF (-1.27%) - Ping An CSI Photovoltaic Industry ETF (-1.23%) [4][5] ETF Fund Flows - The top three ETFs by fund inflow were: - Huatai Baichuan CSI 300 ETF (inflow of 761 million yuan) - Southern CSI 500 ETF (inflow of 581 million yuan) - Huaxia CSI A500 ETF (inflow of 458 million yuan) [6][7] - The ETFs with the largest outflows included: - Huabao CSI All Share Securities Company ETF (outflow of 442 million yuan) - Huatai CSI Dividend ETF (outflow of 401 million yuan) - Fortune CSI Composite Index ETF (outflow of 191 million yuan) [6][7] ETF Margin Trading Overview - The top three ETFs by margin buying were: - Huaxia Shanghai Stock Exchange Sci-Tech Innovation Board 50 ETF (563 million yuan) - Huatai Baichuan CSI 300 ETF (391 million yuan) - Guotai CSI All Share Securities Company ETF (378 million yuan) [8][9] - The highest margin selling amounts were for: - Huatai Baichuan CSI 300 ETF (33.976 million yuan) - Huaxia Shanghai Stock Exchange 50 ETF (20.749 million yuan) - Huaxia Shanghai Stock Exchange Sci-Tech Innovation Board 50 ETF (4.698 million yuan) [8][9] Industry Insights - Guoyuan Securities is optimistic about the overall recovery of the engineering machinery industry, suggesting a focus on export chain targets with strong overseas production capabilities and diversified clients [10] - Huachuang Securities anticipates accelerated recovery in the industry due to increased project planning and special bond issuance, alongside rigid demand for equipment updates and regulatory interventions [10]